223 related articles for article (PubMed ID: 32932224)
21. Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour.
Rebuzzi SE; Grassi M; Catalano F; Buscaglia M; Bertulli R; Satragno C; Belgioia L; Comandini D
Anticancer Drugs; 2020 Jan; 31(1):80-84. PubMed ID: 31567307
[TBL] [Abstract][Full Text] [Related]
22. Diffuse-Type Tenosynovial Giant Cell Tumor of the Thoracic Spine: Appearance on FDG PET/CT.
Shen G; Ma H; Pan L; Su M; Kuang A
Clin Nucl Med; 2019 Aug; 44(8):e477-e478. PubMed ID: 31274627
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of Tenosynovial Giant Cell Tumor of the Foot and Ankle.
Barnett JR; Rudran B; Khan A; O'Reilly-Harbidge S; Patel S; Malhotra K; Cullen N; Welck M; Aston W
Foot Ankle Int; 2023 Oct; 44(10):1013-1020. PubMed ID: 37644900
[TBL] [Abstract][Full Text] [Related]
24. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
Palmerini E; Longhi A; Donati DM; Staals EL
Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
[TBL] [Abstract][Full Text] [Related]
25. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
26. Diffuse-Type Tenosynovial Giant Cell Tumor of the Shoulder Evaluated by FDG PET/CT.
Tang K; Zheng X; Lin J; Wang L
Clin Nucl Med; 2019 Apr; 44(4):310-312. PubMed ID: 30624274
[TBL] [Abstract][Full Text] [Related]
27. Treatment updates on tenosynovial giant cell tumor.
Palmerini E; Staals EL
Curr Opin Oncol; 2022 Jul; 34(4):322-327. PubMed ID: 35837703
[TBL] [Abstract][Full Text] [Related]
28. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
Jager PL; Gietema JA; van der Graaf WT
Nucl Med Commun; 2004 May; 25(5):433-8. PubMed ID: 15100500
[TBL] [Abstract][Full Text] [Related]
29. MRI of diffuse-type tenosynovial giant cell tumour in the knee: a guide for diagnosis and treatment response assessment.
Spierenburg G; Suevos Ballesteros C; Stoel BC; Navas Cañete A; Gelderblom H; van de Sande MAJ; van Langevelde K
Insights Imaging; 2023 Feb; 14(1):22. PubMed ID: 36725759
[TBL] [Abstract][Full Text] [Related]
30. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
[TBL] [Abstract][Full Text] [Related]
31. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
Choi H; Charnsangavej C; de Castro Faria S; Tamm EP; Benjamin RS; Johnson MM; Macapinlac HA; Podoloff DA
AJR Am J Roentgenol; 2004 Dec; 183(6):1619-28. PubMed ID: 15547201
[TBL] [Abstract][Full Text] [Related]
32. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
33. Arthroscopic Excision of a Localized Tenosynovial Giant Cell Tumor of the Knee: A Case Report.
Zmerly H; Draghetti M; Moscato M; Akkawi I
Curr Rheumatol Rev; 2024; 20(4):459-464. PubMed ID: 38231053
[TBL] [Abstract][Full Text] [Related]
34. CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.
Peterfy C; Chen Y; Countryman P; Chmielowski B; Anthony SP; Healey JH; Wainberg ZA; Cohn AL; Shapiro GI; Keedy VL; Singh A; Puzanov I; Wagner AJ; Qian M; Sterba M; Hsu HH; Tong-Starksen S; Tap WD
Future Oncol; 2022 Apr; 18(12):1449-1459. PubMed ID: 35040698
[No Abstract] [Full Text] [Related]
35. Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives.
Staals EL; Ferrari S; Donati DM; Palmerini E
Eur J Cancer; 2016 Aug; 63():34-40. PubMed ID: 27267143
[TBL] [Abstract][Full Text] [Related]
36. Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets.
van der Heijden L; Spierenburg G; Kendal JK; Bernthal NM; van de Sande MAJ
J Surg Oncol; 2023 Sep; 128(3):478-488. PubMed ID: 37537982
[TBL] [Abstract][Full Text] [Related]
37. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
Brahmi M; Vinceneux A; Cassier PA
Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289
[TBL] [Abstract][Full Text] [Related]
38. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy.
Capirci C; Rampin L; Erba PA; Galeotti F; Crepaldi G; Banti E; Gava M; Fanti S; Mariani G; Muzzio PC; Rubello D
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1583-93. PubMed ID: 17503039
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of a diffuse type tenosynovial giant cell tumor in the thoracic spine mimicking spinal metastasis by frozen recapping laminoplasty in a patient with thyroid cancer.
Yonezawa N; Murakami H; Kato S; Hayashi H; Tsuchiya H
Eur Spine J; 2018 Jul; 27(Suppl 3):526-532. PubMed ID: 29663145
[TBL] [Abstract][Full Text] [Related]
40. Prognosis of Advanced Tenosynovial Giant Cell Tumor of the Knee Diagnosed During Total Knee Arthroplasty.
Lei P; Sun R; Liu H; Zhu J; Wen T; Hu Y
J Arthroplasty; 2017 Jun; 32(6):1850-1855. PubMed ID: 28161138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
